Literature DB >> 8977655

Survey of diplomates of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons regarding clinical aspects and treatment of endotoxemia in horses.

R Shuster1, J Traub-Dargatz, G Baxter.   

Abstract

A questionnaire designed to elicit information concerning prevalence, underlying causes, diagnosis, prevention, treatment, and complications of endotoxemia in horses was mailed to diplomates of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons who identified themselves as equine practitioners. Gastrointestinal tract compromise, conditions associated with foaling, and grain overload were reported to be the most common clinical conditions that led to endotoxemia. Most of the respondents diagnosed endotoxemia on the basis of the following clinical and laboratory findings: neutropenia, leukopenia, hyperemic mucous membranes, tachycardia, and fever. Treatments used to attempt to prevent development of endotoxemia or to treat horses with endotoxemia included i.v. fluids and administration of broad-spectrum antimicrobials and flunixin meglumine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8977655

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  2 in total

1.  Chemical chaperones reverse early suppression of regulatory circuits during unfolded protein response in B cells from common variable immunodeficiency patients.

Authors:  D Bhatt; R C Stan; R Pinhata; M Machado; S Maity; C Cunningham-Rundles; C Vogel; M M de Camargo
Journal:  Clin Exp Immunol       Date:  2020-01-09       Impact factor: 4.330

2.  Lipopolysaccharide-induced inhibition of transcription of tlr4 in vitro is reversed by dexamethasone and correlates with presence of conserved NFκB binding sites.

Authors:  Camila P Bonin; Raquel Y A Baccarin; Katarina Nostell; Laila A Nahum; Caroline Fossum; Maristela M de Camargo
Journal:  Biochem Biophys Res Commun       Date:  2013-02-10       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.